News

  • CEM shows promise for screening high-risk breast cancer patients

    Contrast-enhanced mammography (CEM) has shown promise for women at higher risk of breast cancer, with follow-up screening showing greater specificity and accuracy. Cancer detection rates remained consistent during repeat screening, while specificity improved compared with baseline examinations. Specificity shows how accurately a test identifies people who do not have the disease, helping to reduce unnecessary [...]

  • Premature menopause is a high blood pressure risk, study finds

    Premature menopause is linked to a higher risk of developing high blood pressure, according to a study of more than 107,000 women. The risk was highest among women who reached menopause between the ages of 25 and 35. Researchers said the findings support earlier cardiovascular screening for women who reach menopause before the age of [...]

  • Natural Cycles receives sixth FDA clearance for fertility algorithm

    Natural Cycles has received its sixth FDA clearance for an updated fertility algorithm designed to personalise digital contraception. The regulator cleared the company’s next-generation NC° Fertility Algorithm, which combines statistical modelling with machine learning to predict fertile and non-fertile days. Natural Cycles said the algorithm was trained on tens of millions of real-world [...]

  • Experimental treatment significantly slows progression of fatal brain disease in women, study finds

    Davunetide may significantly slow the progression of a fatal brain disease in women, according to a new analysis of clinical trial data. The findings indicate that women and men with progressive supranuclear palsy (PSP) may respond differently to the experimental treatment. Progressive supranuclear palsy, or PSP, is a rare and fatal neurodegenerative disease. [...]

  • UK research paves way for new preeclampsia therapies

    A preeclampsia study has found unusual cell activity in mothers and babies that could reveal new targets for treatment. The condition affects 2 to 4 per cent of pregnancies worldwide and is a leading cause of maternal and foetal mortality. There is currently no cure, and severe cases can put both the mother and baby [...]

  • Planetary Health Diet lowers heart risk in older women, study finds

    A 20-year study of 66,892 postmenopausal women linked the Planetary Health Diet to lower cardiovascular disease risk. Women whose eating habits most closely followed the diet had around a 28 per cent lower risk of cardiovascular disease than those in the lowest-adherence group. Even moderate adherence to the diet was linked with a lower risk. [...]

  • Fertility startup American Baby Company secures US$4m

    A fertility startup has raised US$4m and will open its first lower-cost IVF clinic in West Palm Beach later this year. It will offer a full IVF cycle, including medications, for US$8,995. Around 12 per cent of American couples struggle with infertility, according to the company, but only 14 per cent of them [...]

  • Yoga and omega-3 as effective as therapy for depression in pregnancy, research finds

    Yoga and omega-3 supplements may be as effective as talking therapies for pregnancy depression, a major review suggests. Globally, nearly one in three pregnant women experience depression, but most receive no treatment. When support is available, women are often directed towards talking therapies such as cognitive behavioural therapy, or CBT, and mindfulness. CBT [...]

  • Type 2 diabetes rising among young women, experts warn

    Type 2 diabetes is rising among women in their 20s in England, with experts warning of a worrying increase since the Covid pandemic. The rise has largely occurred since the pandemic and is closely linked to increasing obesity levels, according to an analysis of NHS data from 2011 to 2024. The condition is serious and [...]

  • AstraZeneca drug approved for breast cancer in EU

    AstraZeneca’s breast cancer drug Etcamah has been approved in the EU as part of a combination treatment for advanced disease. The European Commission acted on a positive opinion from the Committee for Medicinal Products for Human Use, the Cambridge, England-based drug maker said. The decision followed positive results from the Serena-6 phase III [...]